

103<sup>D</sup> CONGRESS  
1<sup>ST</sup> SESSION

# H. R. 437

To provide for research on antiprogestin drugs through the National Institutes of Health.

---

## IN THE HOUSE OF REPRESENTATIVES

JANUARY 5, 1993

Mr. WYDEN (for himself, Mr. WAXMAN, Mrs. SCHROEDER, and Mr. DEFAZIO) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To provide for research on antiprogestin drugs through the National Institutes of Health.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Antiprogestin Testing  
5 Act of 1993”.

6 **SEC. 2. RESEARCH.**

7 (a) IN GENERAL.—The Secretary of Health and  
8 Human Services, acting through the Director of the Na-  
9 tional Institutes of Health, may conduct and support re-  
10 search (including clinical trials) on antiprogestin drugs for

1 their safety and efficacy for any potential use, including  
2 termination of pregnancy and contraception, and when  
3 used therapeutically for cancer, endocrine disorders, and  
4 endometriosis.

5 (b) INSTITUTIONAL REVIEW BOARDS AND PEER RE-  
6 VIEW.—Research conducted or supported under sub-  
7 section (a) shall be subject to sections 491 and 492 of  
8 the Public Health Service Act (42 U.S.C. 289, 289a).

9 (c) PRIORITIES.—In determining priorities for re-  
10 search under subsection (a), the Secretary shall consider  
11 data from previous research.

12 **SEC. 3. REPORT.**

13 The Secretary of Health and Human Services shall  
14 report to Congress the results of research conducted or  
15 supported under section 2(a) on January 1, 1994, and  
16 annually thereafter.

○